AMGN — Amgen Inc.
$439.26-1.79%
Last close: · regular session
After-hours $439.26 0.00% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for AMGN in the TickerWise workspace.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NASDAQ
- Employees: 28,000
- Website: https://www.amgen.com
Latest SEC filings for AMGN
Latest AMGN news
- Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? Read article
- Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? Read article
- Here's Why Amgen (AMGN) Fell More Than Broader Market Read article
- Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Read article
- Amgen to Present at the European Society of Medical Oncology Congress 2026 Read article
- Amgen, AstraZeneca report phase 3 results for Tezspire in eosinophilic esophagitis Read article
- Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know Read article
- Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.